6 news items
Morgan Stanley Maintains Equal-Weight on Galapagos, Maintains $38 Price Target
GLPG
22 Apr 24
Morgan Stanley analyst Judah Frommer maintains Galapagos (NASDAQ:GLPG) with a Equal-Weight and maintains $38 price target.
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
GILD
GLPG
1 Apr 24
the price target from $41 to $31.
Galapagos is currently conducting three early
B of A Securities Downgrades Galapagos to Underperform, Lowers Price Target to $31
GLPG
28 Mar 24
B of A Securities analyst Jason Gerberry downgrades Galapagos (NASDAQ:GLPG) from Neutral to Underperform and lowers the price target from $41 to $31.
Morgan Stanley Assumes Galapagos at Equal-Weight, Announces Price Target of $38
GLPG
7 Mar 24
Morgan Stanley analyst Judah Frommer assumes Galapagos (NASDAQ:GLPG) with a Equal-Weight rating and announces Price Target of $38.
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
GLPG
22 Feb 24
otherwise undruggable disease-causing targets, today announced the close of an oversubscribed $80 million Series C financing. The financing was co
jyabvh96txr10kkvmvy1d6sp3ke0mgmo5comukute
GLPG
22 Feb 24
or efficacy concerns or other reasons), the inherent risks and uncertainties associated with target discovery and validation and drug discovery and development
- Prev
- 1
- Next